Disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, azathioprine, and anti-TNF-α agents, were prescribed to 4 patients (33.3%) due to ongoing inflammation characterized by osteitis and colitis. The gene discussed is TNF; the disease is colitis.